As of 14 Oct 2026, Ethyreal Bio has raised $101M across 1 verified round on record; latest: $101 million Series A, announced 10 Jun 2026.
Ethyrealbio develops investigational therapies targeting Thyroid Eye Disease and Graves' Disease for patients.
ethyrealbio.comLinkedInMassachusettsBiotech
1 source
The article does not break out the $101 million between the Series A and Series B rounds.
Published by hand (fiercebiotech.com): "(iStock/Getty Images Plus) Ethyreal Bio has exited stealth with $101 million in funding, joining the queue of companies preparing to challenge Amgen’s Tepezza.": Checked by hand: Fierce Biotech states the $101M.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A series A and B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $101M | 2026-06-10 | not stated | No recent discussion |
1 source [ VERIFIED · CORRECTED ] read against 1 source
The article does not break out the $101 million between the Series A and Series B rounds. Published by hand (fiercebiotech.com): "(iStock/Getty Images Plus) Ethyreal Bio has exited stealth with $101 million in funding, joining the queue of companies preparing to challenge Amgen’s Tepezza.": Checked by hand: Fierce Biotech states the $101M. | ||||